Jazz Pharmaceuticals Aktie

216,20 EUR -1,10 EUR -0,51 %

22:43:14

BMN

246,99 USD -1,25 USD -0,50 %

21:59:56

BTT

Jazz Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.13,60 Mrd. EUR

Div. Rendite0,00%

WKNA1JS1K

ISINIE00B4Q5ZN47

SymbolJAZZ

Jazz Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

08.05.26finanzen.netJazz Pharmaceuticals stellte Zahlen zum jüngsten Quartal vor

26.02.26finanzen.netJazz Pharmaceuticals hat die Zahlen zum jüngsten Quartal vorgelegt

23.02.26finanzen.netAusblick: Jazz Pharmaceuticals verkündet Quartalsergebnis zum jüngsten Jahresviertel

WerbungJazz Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

08.01.26PR NewswireJazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

06.01.26PR NewswireZiihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit

17.12.25PR NewswireJazz Pharmaceuticals to Participate in Upcoming Investor Events

05.12.25PR NewswireJazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 An...

02.12.25PR NewswireJazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at th...

18.11.25PR NewswireJazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

17.11.25TraderFoxStocks in Action USA

Stocks in Action USA: Quantum Computing, Jazz Pharmaceuticals, Elbit Systems

17.11.25PR NewswirePositive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Lo...

11.11.25PR NewswireJazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025

07.11.25finanzen.netJazz Pharmaceuticals stellte Ergebnisse des abgelaufenen Quartals vor

05.11.25PR NewswireJazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance

04.11.25finanzen.netAusblick: Jazz Pharmaceuticals stellt Ergebnisse des abgelaufenen Quartals vor

28.10.25PR NewswireJazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

22.10.25PR NewswireJazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025

03.10.25PR NewswireFDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

22.09.25PR NewswireJazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psy...

09.09.25PR NewswireModeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma

21.08.25PR NewswireJazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference

20.08.25PR NewswireJazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

20.08.25PR NewswireJazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

07.08.25finanzen.netJazz Pharmaceuticals: Bilanzvorlage zum letzten Quartal

06.08.25PR NewswireJazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

05.08.25PR NewswireJazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance

04.08.25finanzen.netAusblick: Jazz Pharmaceuticals legt Quartalsergebnis vor

22.07.25PR NewswireJazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

10.07.25PR NewswireJazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

01.07.25PR NewswireJazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

10.06.25PR NewswireZepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals News

Jazz Pharmaceuticals News: auf dieser Seite finden Sie alle Jazz Pharmaceuticals News und Nachrichten zur Jazz Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Jazz Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Jazz Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.